Form 4: Fortress Biotech Director Hoenlein Receives Restricted Stock Grant

Malcolm Hoenlein, a director at Fortress Biotech, was granted 49,383 shares of restricted stock under the company's 2013 Stock Incentive Plan.

Summary

• Malcolm Hoenlein, a director of Fortress Biotech, received 49,383 shares of restricted stock on January 1, 2025.
• The grant was made under the Issuer's 2013 Stock Incentive Plan, as amended.
• The shares vest in three equal installments on January 1 of 2026, 2027, and 2028, contingent upon continued service.
• Hoenlein elected to defer 25% of these restricted shares, receiving deferred share units instead, which are subject to the same vesting conditions.
• Vested deferred shares will be delivered in January following termination of service, or earlier upon death or change in control.
• Following the transaction, Hoenlein beneficially owns 88,425 shares, including 45,676 shares underlying deferred restricted stock units.

Sentiment

Score: 6

Explanation: The document is a neutral disclosure of a stock grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The grant of restricted stock aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Risks

• The vesting of the restricted stock is contingent upon continued service, which could be a risk if the director leaves the company before full vesting.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of stock grants to company insiders, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Stakeholder Impact

• The stock grant could have a slightly dilutive effect on existing shareholders.
• The vesting schedule incentivizes the director to remain with the company, which could benefit stakeholders.

Key Dates